Dr. Mehta received his BA in Biology from Illinois Wesleyan University and an MD from University of Texas-Southwestern Medical School. He completed his residency in Internal Medicine at University of Illinois-Chicago Hospital. He completed a clinical research fellowship in complementary and integrative medicine at the Harvard Medical School Osher Research Center (now based at the Beth Israel Deaconess Medical Center Division of General Medicine), during which he received a Master of Public Health degree from the Harvard School of Public Health.
He is presently the Medical Director of the Benson-Henry Institute for Mind Body Medicine at Massachusetts General Hospital, and Associate Director of Education for the Osher Center for Integrative Medicine at Brigham & Women’s Hospital and Harvard Medical School. His educational and research interests include curricular development in complementary and integrative medical therapies, mind/body educational interventions in health professions training, and promotion of professionalism in medical trainees. He directs medical student and resident rotational experiences in integrative medicine for BHI-MGH and the Osher Center for Integrative Medicine. Dr. Mehta sees patients in a consultative role for use of complementary and integrative medical therapies, as well as mind/body interventions for stress management and stress reduction.
Dr. Mehta is an Instructor in Medicine at Harvard Medical School. He is also active in the Massachusetts Medical Society, and is a member of the American College of Physicians. Dr. Mehta is a diplomate of the American Board of Holistic Medicine, and has completed professional training in mindfulness-based stress reduction at the University of Massachusetts Medical School.
Moderated by Aaron Blackledge (MD, Care Practice), this panel includes demonstrations from James Davis (COO, RegisterPatient), Arien Malec (VP Data Platform Solutions, Relay Health), Daniel Kivatinos (Co-Founder & COO, Dr. Chrono), Russell Olsen (Vice President, Product Management, Phytel), Matt Wiggins (Remedy Systems), and commentary by Ronald Dixon (Medical Director, Massachusetts General Hospital).